Animal & cell study / 1998

Ipamorelin, the first selective growth hormone secretagogue

Raun K, Hansen BS, Johansen NL, et al.

Study overview

Preclinical pharmacology characterized the pentapeptide ipamorelin and compared growth hormone release with other secretagogues in laboratory models.

Results are specific to the study. This is an editorial summary, not personal treatment advice.

Study limitations

Selectivity in these models does not establish long-term human safety or benefits for sleep, injury recovery, or athletic performance.

About this summary

This summary uses the cited abstract and bibliographic record. Read the original methods and results for the full context.